BullFrog AI Holdings is a digital biopharmaceutical company that uses artificial intelligence and machine learning to analyze complex biomedical data. It is a stock, not an exchange-traded fund, and it is a micro-cap issue with a market capitalization near $13 million.
Unlike larger companies, BFRG has no meaningful analyst price-target coverage. MarketBeat and other aggregators list the consensus price target as "N/A," and the handful of available ratings—one sell and one hold—carry no actionable price objectives. Some data feeds even display an obviously erroneous multi-million-dollar target that has no basis in any attributable analyst report. For that reason, no analyst-derived average can be calculated.
Instead, the $1.00 figure used here comes from a well-documented, publicly discussed objective: the Nasdaq minimum bid price requirement. BullFrog AI received a notice on February 10, 2026, that its stock had closed below $1.00 for 30 consecutive business days, placing it out of compliance. Regaining the $1.00 threshold for a sustained period is the single most concrete price objective the company and its investors are currently discussing, making it a realistic reference point rather than an arbitrary forecast.
BFRG shares closed at approximately $0.69 on October 6, 2026, and traded in a 52-week range of about $0.43 to $2.04. Reaching $1.00 would require a move of roughly 45%, a substantial advance by any measure and well above the stock's recent trading levels.
The path toward that figure runs through both fundamentals and regulation. On the operational side, the company signed its first commercial feasibility agreement with a top-five global pharmaceutical company in March 2026, applying its bfLEAP platform to identify drug targets in major depressive disorder. Management has said financing completed in late March 2026 provides a runway into late 2027. However, trailing twelve-month revenue remains only about $300,000, and the company continues to generate significant net losses.
On the regulatory side, Nasdaq granted a second 180-day compliance period on August 18, 2026, extending the deadline to February 8, 2027. Shareholders previously approved a reverse stock split at a ratio between 1-for-2 and 1-for-15, which management has indicated it could use if the share price does not recover on its own.
Several verified factors could support a recovery toward $1.00. The March 2026 agreement with a major pharmaceutical company provides commercial validation of the bfLEAP platform and creates milestone-payment opportunities. The company reports active enterprise discussions with other pharmaceutical and biotechnology organizations, and it launched bfARENAS, a scenario-based decision engine, to broaden its platform offering.
Insider activity has also been constructive. In September 2026, CEO Vininder Singh purchased 75,000 shares and CFO Joshua Blacher purchased 50,000 shares in open-market transactions, moves some investors read as a vote of confidence. A strengthened balance sheet, with stockholders' equity reported above Nasdaq's minimum requirement, reduces near-term financing pressure. A reverse stock split, while not creating value, could mechanically restore compliance and support the stated price level.
The obstacles are equally significant. BullFrog AI has generated minimal revenue relative to its valuation—the stock trades at a price-to-sales ratio above 40 times trailing revenue—and remains deeply unprofitable, with a reported loss of about $6 million over the trailing twelve months.
Dilution is a persistent risk: the share count has risen by roughly 46% over the past year as the company has used at-the-market and equity-line facilities. A reverse stock split could also trigger further selling or renewed volatility. Most importantly, if the bid price does not stay above $1.00 for the required period, the company faces delisting, which would reduce liquidity and market visibility regardless of any fundamental progress.
The stock's long-term trend remains under pressure, with the share price down more than 50% over the past year. The $1.00 mark is the most meaningful psychological and regulatory resistance level, because it doubles as the Nasdaq compliance threshold. The 52-week high near $2.04, set in October 2025, marks a distant upper boundary, while the 52-week low near $0.43 represents a key support zone. A durable close above $1.00 for ten consecutive business days is the specific condition Nasdaq has described for confirming compliance.
Because there is no analyst target with a stated research horizon, no 12-month time frame can be attributed to the $1.00 objective. The most concrete deadline is February 8, 2027, the end of the second Nasdaq compliance period. Investors should watch the company's next earnings report, estimated for mid-November 2026, for updates on the pharmaceutical agreement, milestone payments, and cash burn. Other items to monitor include any reverse-split announcement, additional insider transactions, new partnership signings, and the stock's ability to sustain trading above $1.00.
Traders following volatile micro-caps like BFRG can supplement fundamental research with AI Daily Buy/Sell Signals. Tickeron's artificial intelligence continuously monitors thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. This tool helps traders discover opportunities, monitor existing positions, and identify changing trends more efficiently than manual scanning allows. Explore Tickeron's AI Daily Buy/Sell Signals to see how machine-driven signals can fit into your research process.
The question of whether BFRG can reach $1.00 is less a matter of analyst price targets—none exist—than of whether the company can restore Nasdaq compliance and sustain investor confidence. At roughly $0.69, the stock would need a substantial advance of about 45% to touch that level. The strongest supports are commercial validation from a major pharmaceutical partner, a funded runway, and insider buying, while the principal obstacles are minimal revenue, continued losses, share dilution, and the threat of delisting. There is no consensus among analysts to lean on, and the outcome will depend heavily on execution, partnership milestones, and any decision to pursue a reverse stock split. No target should be treated as a guarantee, and investors should monitor earnings, regulatory filings, and the stock's behavior near the $1.00 threshold.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BFRG has been loosely correlated with PDFS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if BFRG jumps, then PDFS could also see price increases.
| Ticker / NAME | Correlation To BFRG | 1D Price Change % | ||
|---|---|---|---|---|
| BFRG | 100% | -6.43% | ||
| PDFS - BFRG | 39% Loosely correlated | -10.94% | ||
| AI - BFRG | 38% Loosely correlated | -2.83% | ||
| NTCT - BFRG | 37% Loosely correlated | -3.79% | ||
| PATH - BFRG | 37% Loosely correlated | -1.43% | ||
| DUOL - BFRG | 36% Loosely correlated | -0.26% | ||
More | ||||
| Ticker / NAME | Correlation To BFRG | 1D Price Change % |
|---|---|---|
| BFRG | 100% | -6.43% |
| Services to the Health Industry industry (42 stocks) | 5% Poorly correlated | -1.71% |
| Health Services industry (240 stocks) | -3% Poorly correlated | -1.68% |